LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that a new study highlighting the use of Simoa technology to measure amyloid beta in blood has been published in Scientific Reports, a publication of the Nature Publishing Group. The study, authored by Dr. Stefania Mondello from the University of Messina in Italy, showed that measurements of amyloid beta 1-42 (Aß42), a brain protein thought to be a possible marker for brain injury, did in fact correlate with mortality when measured in plasma by Simoa.
Currently, diagnosing a brain injury is a combination of both subjective cognitive assessments and expensive imaging techniques, but no simple blood test exists. The importance of traumatic brain injury diagnosis has recently been recognized by the National Football League (NFL), who found that concussions experienced by its players may cause brain injury with long term health impacts. Other groups representing athletes across a range of sports and levels have also become increasingly concerned, as has the military for soldiers exposed to detonations of improvised explosive devices (IEDs) and other head injuries.
Help employers find you! Check out all the jobs and post your resume.
